Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes

Anti-Cancer Drugs

Volumn 23, Issue 4, 2012, Pages 370-379

  Tin, Antony S ^a   Sundar, Shyam N ^a   Tran, Kalvin Q ^a   Park, Anna H ^a   Poindexter, Kevin M ^a   Firestone, Gary L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

artemisinin; breast cancer cells; cyclin dependent kinases 2 gene expression and promoter activity; E2F1 transcription factor; G1 cell cycle arrest

Indexed keywords

ARTEMISININ; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; LUCIFERASE; TRANSCRIPTION FACTOR E2F1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; EARLY CANCER; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ARTEMISININS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; E2F1 TRANSCRIPTION FACTOR; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84858284701     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834f6ea8     Document Type: Article

References (54)

1. Cianfrocca M, Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin 2009; 59:303-313.
2. Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
3. Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP Nawaz Z, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991; 51:105-109.
4. Darbre PD, Daly RJ. Transition of human breast cancer cells from an oestrogen responsive to unresponsive state. J Steroid Biochem Mol Biol 1990; 37:753-763.
5. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007; 7:791-799. (Pubitemid 47463670)
6. Wang T, You Q, Huang FS, Xiang H. Recent advances in selective estrogen receptor modulators for breast cancer. Mini Rev Med Chem 2009; 9: 1191-1201.
7. Abdulhaq H, Geyer C. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer. Am J Clin Oncol 2008; 31:595-605.
8. Arslan C, Dizdar O, Altundag K. Pharmacotherapy of triple-negative breast cancer. Expert Opin Pharmacother 2009; 10:2081-2093.
9. Aapro M, Monfardini S, Jirillo A, Basso U. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat Rev 2009; 35:503-508.
10. Scott EN, Gescher AJ, Steward WP, Brown K. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila) 2009; 2:525-530.
11. Brasseur P, Badiane M, Cisse M, Agnamey P, Vaillant MT, Olliaro PL. Changing patterns of malaria during 1996-2010 in an area of moderate transmission in Southern Senegal. Malar J 2011; 10:203.
12. Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. Mayo Clin Proc 2011; 86:561-583.
13. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32:1655-1660. (Pubitemid 35339455)
14. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The antimalarial artesunate is also active against cancer. Int J Oncol 2001; 18: 767-773.
15. Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, et al. Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med 2011; 6:27.
16. Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul W, et al. Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer 2009; 125:1266-1275.
17. Firestone GL, Sundar SN. Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 2009; 11:e32.
18. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets 2006; 7:407-421. (Pubitemid 43744832)
19. Efferth T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin: from bench to bedside. Planta Med 2007; 73: 299-309. (Pubitemid 46910410)
20. Dell'Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A, et al. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 2004; 68:2359-2366. (Pubitemid 39535108)
21. Bustos MD, Gay F, Diquet B. In-vitro tests on Philippine isolates of Plasmodium falciparum against four standard antimalarials and four qinghaosu derivatives. Bull World Health Organ 1994; 72:729-735. (Pubitemid 24344096)
22. Meshnick SR, Thomas A, Ranz A, Xu CM, Pan HZ. Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. Mol Biochem Parasitol 1991; 49:181-189.
23. Efferth T, Olbrich A, Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol 2002; 64:617-623.
24. Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008; 14:5519-5530.
25. Willoughby JA Sr, Sundar SN, Cheung M, Tin AS, Modiano J, Firestone GL. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 2009; 284:2203-2213.
26. Sundar SN, Marconett CN, Doan VB, Willoughby JA Sr, Firestone GL. Artemisinin selectively decreases functional levels of estrogen receptoralpha and ablates estrogen-induced proliferation in human breast cancer cells. Carcinogenesis 2008; 29:2252-2258.
27. Nguyen HH, Lavrenov SN, Sundar SN, Nguyen DH, Tseng M, Marconett CN, et al. 1-Benzyl-indole-3-carbinol is a novel indole-3-carbinol derivative with significantly enhanced potency of anti-proliferative and anti-estrogenic properties in human breast cancer cells. Chem Biol Interact 2010; 186:255-266.
28. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24: 148-154. (Pubitemid 19163397)
29. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004; 83:249-289. (Pubitemid 38264873)
30. Levenson AS, Jordan VC. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 1997; 57:3071-3078. (Pubitemid 27351713)
31. Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 1995; 91:41-46.
32. He Y, Fan J, Lin H, Yang X, Ye Y, Liang L, et al. The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1alpha in human rheumatoid arthritis fibroblast-like synoviocyte. Rheumatol Int 2011; 31:53-60.
33. Chen HH, Zhou HJ, Wang WQ, Wu GD. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol 2004; 53: 423-432.
34. Posner GH, McRiner AJ, Paik IH, Sur S, Borstnik K, Xie S, et al. Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J Med Chem 2004; 47:1299-1301. (Pubitemid 38229132)
35. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003; 64:382-394. (Pubitemid 36910002)
36. Zetterberg A, Larsson O, Wiman KG. What is the restriction point? Curr Opin Cell Biol 1995; 7:835-842.
37. Araki K, Nakajima Y, Eto K, Ikeda MA. Distinct recruitment of E2F family members to specific E2F-binding sites mediates activation and repression of the E2F1 promoter. Oncogene 2003; 22:7632-7641. (Pubitemid 37464097)
38. Bonin S, Brunetti D, Benedetti E, Gorji N, Stanta G. Expression of cyclindependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer. Virchows Arch 2006; 448:539-544. (Pubitemid 44490550)
39. Wang CH, Chang HC, Hung WC. p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription. J Cell Physiol 2006; 208:246-252. (Pubitemid 43849011)
40. Garcia HH, Brar GA, Nguyen DH, Bjeldanes LF, Firestone GL. Indole-3- carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex. J Biol Chem 2005; 280:8756-8764. (Pubitemid 40409563)
41. Hung WC, Chang HC. Indole-3-carbinol inhibits Sp1-induced matrix metalloproteinase-2 expression to attenuate migration and invasion of breast cancer cells. J Agric Food Chem 2009; 57:76-82.
42. Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, et al. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 2006; 12: 3319-3328.
43. Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, et al. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 2000; 9:395-401. (Pubitemid 30265783)
44. Chen H, Sun B,Wang S, Pan S, Gao Y, Bai X, et al. Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. J Cancer Res Clin Oncol 2010; 136:897-903.
45. Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, et al. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol 2008; 74:476-484.
46. Wang Y, Huang Z,Wang L, Meng S, Fan Y, Chen T, et al. The anti-malarial artemisinin inhibits pro-inflammatory cytokines via the NF-kappaB canonical signaling pathway in PMA-induced THP-1 monocytes. Int J Mol Med 2011; 27:233-241.
47. Steinbruck L, Pereira G, Efferth T. Effects of artesunate on cytokinesis and G/M cell cycle progression of tumour cells and budding yeast. Cancer Genomics Proteomics 2010; 7:337-346.
48. Huang XF, Yuan D, Zhang CC, Zhang XP. Artesunate induces prostate cancer cell line PC-3 differentiation and cell cycle arrest. Zhong Xi Yi Jie He Xue Bao 2008; 6:591-594. (Pubitemid 351895366)
49. Antalis CJ, Uchida A, Buhman KK, Siddiqui RA. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clin Exp Metastasis 2011; 28:733-741.
50. Ferguson AT, Vertino PM, Spitzner JR, Baylin SB, Muller MT, Davidson NE. Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2'-deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem 1997; 272: 32260-32266. (Pubitemid 28011904)
51. Worsham MJ, Pals G, Schouten JP, Miller F, Tiwari N, Van Spaendonk R, et al. High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat 2006; 96:177-186.
52. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990; 50:6075-6086. (Pubitemid 20331424)
53. Lai H, Sasaki T, Singh NP, Messay A. Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci 2005; 76:1267-1279. (Pubitemid 40092141)
54. Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 2007; 28: 1045-1056. (Pubitemid 47020494)